We are live on
!
Find out more
BM
Brandywine Managers Portfolio holdings
AUM
$170M
1-Year Est. Return
10.01%
This Fund
S&P 500
This Quarter
Est. Return
-10.49%
1 Year Est. Return
+10.01%
3 Year Est. Return
+53.1%
5 Year Est. Return
+7.42%
10 Year Est. Return
+248.69%
AUM
$212M
AUM Growth
-$21.8M
(-9.3%)
Cap. Flow
+$3.58M
Cap. Flow
% of AUM
1.69%
Top 10 Holdings %
Top 10 Hldgs %
92.81%
Holding
48
New
14
Increased
3
Reduced
–
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Twist Bioscience
TWST
|
+$443K |
| 2 |
Neurocrine Biosciences
NBIX
|
+$345K |
| 3 |
SMAR
Smartsheet Inc.
SMAR
|
+$341K |
| 4 |
Regenxbio
RGNX
|
+$329K |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
+$323K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$466K |
| 2 |
NVIDIA
NVDA
|
+$225K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Staples | 87.27% |
| 2 | Technology | 9.57% |
| 3 | Healthcare | 1.95% |
| 4 | Consumer Discretionary | 0.5% |
| 5 | Industrials | 0.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SMAR
26
DELISTED
Smartsheet Inc.
SMAR
| $341K | 0.16% |
+13,700
| New | +$341K |
|
27
Pegasystems
PEGA
$5.37B
| $311K | 0.15% |
13,000
| – | – |
|
|
28
Alnylam Pharmaceuticals
ALNY
$35.7B
| $306K | 0.14% |
+4,200
| New | +$323K |
|
|
DOCU
29
DocuSign
DOCU
$10.1B
| $301K | 0.14% |
+7,500
| New | +$315K |
|
|
ZUO
30
DELISTED
Zuora, Inc.
ZUO
| $301K | 0.14% |
+16,600
| New | +$319K |
|
|
PLAN
31
DELISTED
Anaplan, Inc.
PLAN
| $287K | 0.14% |
+10,800
| New | +$267K |
|
32
Zscaler
ZS
$24.2B
| $286K | 0.13% |
+7,300
| New | +$276K |
|
33
Varonis Systems
VRNS
$5.46B
| $270K | 0.13% |
15,300
| – | – |
|
34
Guardant Health
GH
$20.7B
| $267K | 0.13% |
+7,100
| New | +$262K |
|
|
35
Neurocrine Biosciences
NBIX
$17.2B
| $257K | 0.12% |
+3,600
| New | +$345K |
|
36
Arista Networks
ANET
$212B
| $253K | 0.12% |
19,200
| – | – |
|
|
CBLK
37
DELISTED
Carbon Black, Inc. Common Stock
CBLK
| $248K | 0.12% |
+18,500
| New | +$304K |
|
38
Moderna
MRNA
$24.5B
| $246K | 0.12% |
+16,100
| New | +$265K |
|
|
XLNX
39
DELISTED
Xilinx Inc
XLNX
| $238K | 0.11% |
2,800
| – | – |
|
|
40
Regenxbio
RGNX
$511M
| $235K | 0.11% |
+5,600
| New | +$329K |
|
|
PFPT
41
DELISTED
Proofpoint, Inc.
PFPT
| $218K | 0.1% |
2,600
+200
| +8% | +$18.5K |
|
42
Quanterix
QTRX
$182M
| $217K | 0.1% |
+11,857
| New | +$213K |
|
|
ASXC
43
DELISTED
Asensus Surgical, Inc.
ASXC
| $209K | 0.1% |
7,099
| – | – |
|
44
Palo Alto Networks
PANW
$292B
| $207K | 0.1% |
6,600
| – | – |
|
45
Knowles
KN
$3.01B
| $172K | 0.08% |
12,900
| – | – |
|
|
SREV
46
DELISTED
ServiceSource International, Inc.
SREV
| $82K | 0.04% |
+75,879
| New | +$119K |
|
|
47
Advanced Micro Devices
AMD
$808B
| – | – |
-15,100
| Closed | -$466K |
|
|
48
NVIDIA
NVDA
$4.91T
| – | – |
-32,000
| Closed | -$225K |
|
Similar funds
CF
DBFM
CAS
FH
RWFS
RFO
DWM
AGC
Brandywine Managers's Q4 2018 Portfolio in Review
As of Q4 2018, Brandywine Managers held 48 positions worth $212M, down 9.3% from $234M the previous quarter. Its ten largest holdings account for 93% of the portfolio.
Brandywine Managers's Q4 2018 filing shows 14 new, 3 increased and 2 closed positions. Its largest new stake was Twist Bioscience: 19,988 shares worth $462K. The largest sale was Advanced Micro Devices, an estimated $466K.
By sector, the portfolio is most concentrated in Consumer Staples at 87% of assets, down from 88% a quarter earlier, followed by Technology and Healthcare.
- Brandywine Managers's largest Q4 2018 buy was Twist Bioscience: 19,988 shares worth $462K.
- Brandywine Managers added most to Teladoc Health in Q4 2018, an estimated $79.5K increase.
- Brandywine Managers fully exited Advanced Micro Devices in Q4 2018, selling an estimated $466K.
- Brandywine Managers's ten largest holdings make up 93% of its $212M portfolio in Q4 2018.
- Brandywine Managers opened 14 new positions and closed 2 in Q4 2018.
- Brandywine Managers's portfolio value fell 9.3% quarter-over-quarter to $212M.
Based on Brandywine Managers's 13F filing for Q4 2018, filed 12 Feb 2019.